Deletion of angiotensin-converting enzyme 2 exacerbates renal inflammation and injury in apolipoprotein E-deficient mice through modulation of the nephrin and TNF-alpha-TNFRSF1A signaling

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Jin, Hai Yan ^a,b   Chen, Lai Jiang ^a,c   Zhang, Zhen Zhou ^a,c   Xu, Ying Le ^a   Song, Bei ^a   Xu, Ran ^a   Oudit, Gavin Y ^d   Gao, Ping Jin ^a,c   Zhu, Ding Liang ^a,b,c   Zhong, Jiu Chang ^a,b,c  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Angiotensin II; Angiotensin converting enzyme 2; Apolipoprotein E; Inflammation; Nephrin; Renal injury

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN[1-7]; APOLIPOPROTEIN E; CREATININE; CYTOKINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPID; NEPHRIN; PROTEIN TNFRSF1A; RANTES; RECOMBINANT ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UREA; ANGIOTENSIN I; ANGIOTENSIN I (1-7); DIPEPTIDYL CARBOXYPEPTIDASE; MEMBRANE PROTEIN; NOX4 PROTEIN, MOUSE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANGIOTENSIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; DOWN REGULATION; GENE DELETION; HISTOPATHOLOGY; KIDNEY DYSFUNCTION; KIDNEY INJURY; KIDNEY STRUCTURE; KNOCKOUT MOUSE; LIPID BLOOD LEVEL; MALE; MOUSE; NEPHRITIS; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; WILD TYPE; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; DEFICIENCY; DRUG EFFECTS; HUMAN; INFLAMMATION; KIDNEY; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; ULTRASTRUCTURE;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; APOLIPOPROTEINS E; GENE DELETION; HUMANS; INFLAMMATION; KIDNEY; MALE; MEMBRANE PROTEINS; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, BIOLOGICAL; NADPH OXIDASE; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SUPEROXIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84938583935     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0616-8     Document Type: Article

References (41)

1. Wen M, Segerer S, Dantas M, Brown PA, Hudkins KL, Goodpaster T et al (2002) Renal injury in apolipoprotein E-deficient mice. Lab Invest 82(8):999-1006
2. Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI et al (2014) Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med 371(24):2267-2276
3. Kon V, Linton MF, Fazio S (2011) Atherosclerosis in chronic kidney disease: the role of macrophages. Nat Rev Nephrol 7(1):45-54
4. Luczak M, Formanowicz D, Marczak Ł, Pawliczak E, Wanic-Kossowska M, Figlerowicz M et al (2015) Deeper insight into chronic kidney disease-related atherosclerosis: comparative proteomic studies of blood plasma using 2DE and mass spectrometry. J Transl Med 13(1):20
5. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S (2001) Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134(8):629-636
6. Mann JF (2005) Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors. Presse Med 34(18):1303-1308
7. Sahara M, Ikutomi M, Morita T, Minami Y, Nakajima T, Hirata Y et al (2014) Deletion of angiotensin-converting enzyme 2 promotes the development of atherosclerosis and arterial neointima formation. Cardiovasc Res 101(2):236-246
8. Zhong J, Guo D, Chen CB, Wang W, Schuster M, Loibner H et al (2011) Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension 57(2):314-322
9. Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M et al (2010) Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122(7):717-728
10. Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, Zhou J et al (2010) Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 59(2):529-538
11. Thomas MC, Pickering RJ, Tsorotes D, Koitka A, Sheehy K, Bernardi S et al (2010) Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ Res 107(7):888-897
12. Candido R, Jandeleit-Dahm KA, Cao Z, Nesteroff SP, Burns WC, Twigg SM et al (2002) Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 106(2):246-253
13. Gagliardini E, Perico N, Rizzo P, Buelli S, Longaretti L, Perico L et al (2013) Angiotensin II contributes to diabetic renal dysfunction in rodents and humans via Notch1/Snail pathway. Am J Pathol 183(1):119-130
14. Jin HY, Song B, Oudit GY, Davidge ST, Yu HM, Jiang YY et al (2012) ACE2 deficiency enhances angiotensin II-mediated aortic profilin-1 expression, inflammation and peroxynitrite production. PLoS One 7:e38502
15. Candido R, Allen TJ, Lassila M, Cao Z, Thallas V, Cooper ME et al (2004) Irbesartan but not amlodipine suppresses diabetes associated atherosclerosis. Circulation 109(12):1536-1542
16. Song B, Zhang ZZ, Zhong JC, Yu XY, Oudit GY, Jin HY et al (2013) Loss of angiotensin-converting enzyme 2 exacerbates myocardial injury via activation of the CTGF-fractalkine signaling pathway. Circ J 77(12):2997-3006
17. Zhang ZZ, Shang QH, Jin HY, Song B, Oudit GY, Lu L et al (2013) Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-deficient mice. J Transl Med. 11:229
18. Patel VB, Zhong JC, Fan D, Basu R, Morton JS, Parajuli N et al (2014) Angiotensin-converting enzyme 2 is a critical determinant of angiotensin II-induced loss of vascular smooth muscle cells and adverse vascular remodeling. Hypertension 64(1):157-164
19. Jiang F, Yang J, Zhang Y, Dong M, Wang S, Zhang Q et al (2014) Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. Nat Rev Cardiol 11(7):413-426
20. Wong DW, Oudit GY, Reich H, Kassiri Z, Zhou J, Liu QC et al (2007) Loss of angiotensin converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol 171(2):438-451
21. Lovren F, Pan Y, Quan A, Teoh H, Wang G, Shukla PC et al (2008) Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol 295(4):H1377-H3784
22. Zhou Q, Desta T, Fenton M, Graves DT, Amar S (2005) Cytokine profiling of macrophages exposed to Porphyromonas gingivalis, its lipopolysaccharide or its fima protein. Infect Immun 73(2):935-943
23. Dias AT, Cintra AS, Frossard JC, Palomino Z, Casarini DE, Gomes IB et al (2014) Inhibition of phosphodiesterase 5 restores endothelial function in renovascular hypertension. J Transl Med 12:250
24. Zhong JC, Yu XY, Lin QX, Li XH, Huang XZ, Xiao DZ et al (2008) Enhanced angiotensin converting enzyme 2 regulates the insulin/Akt signalling pathway by blockade of macrophage migration inhibitory factor expression. Br J Pharmacol 153(1):66-74
25. Zhang Z, Chen L, Zhong J, Gao P, Oudit GY (2014) ACE2/Ang-(1-7) signaling and vascular remodeling. Sci China Life Sci 57(8):802-808
26. Madhur MS, Funt SA, Li L, Vinh A, Chen W, Lob HE et al (2011) Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol 31(7):1565-1572
27. Zhang J, Patel MB, Griffiths R, Mao A, Song YS, Karlovich NS et al (2014) Tumor necrosis factor-aα produced in the kidney contributes to angiotensin II-dependent hypertension. Hypertension 64(6):1275-1281
28. Duerrschmid C, Crawford JR, Reineke E, Taffet GE, Trial J, Entman ML et al (2013) TNF receptor 1 signaling is critically involved in mediating angiotensin-II-induced cardiac fibrosis. J Mol Cell Cardiol 57:59-67
29. Rüster C, Wolf G (2006) Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 17(11):2985-2991
30. Liu Z, Huang XR, Chen HY, Penninger JM, Lan HY (2012) Loss of angiotensin-converting enzyme 2 enhances TGF-β/Smad-mediated renal fibrosis and NF-κB-driven renal inflammation in a mouse model of obstructive nephropathy. Lab Invest 92(5):650-661
31. Schulz R, Heusch G (2009) Tumor necrosis factor-alpha and its receptors 1 and 2: Yin and Yang in myocardial infarction? Circulation 119(10):1355-1357
32. Higuchi Y, McTiernan CF, Frye CB, McGowan BS, Chan TO, Feldman AM (2004) Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-alpha-induced cardiomyopathy. Circulation 109(15):1892-1897
33. Li X, Chuang PY, D'Agati VD, Dai Y, Yacoub R, Fu J et al (2015) Nephrin preserves podocyte viability and glomerular structure and function in adult kidneys. J Am Soc Nephrol. doi: 10.1681/ASN.2014040405
34. Márquez E, Riera M, Pascual J, Soler MJ (2015) Renin-angiotensin system within the diabetic podocyte. Am J Physiol Renal Physiol 308(1):F1-F10
35. Yu S (2014) Role of nephrin in podocyte injury induced by angiotension II. J Recept Signal Transduct Res 29:1-5. doi: 10.3109/10799893.2014.963872
36. Patel VB, Takawale A, Ramprasath T, Das SK, Basu R, Grant MB et al (2015) Antagonism of angiotensin 1-7 prevents the therapeutic effects of recombinant human ACE2. J Mol Med (Berl). doi: 10.1007/s00109-015-1285-z
37. Zhong JC, Ye JY, Jin HY, Yu X, Yu HM, Zhu DL et al (2011) Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression. Regul Pept 166(1-3):90-97
38. Varagic J, Ahmad S, Nagata S, Ferrario CM (2014) ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. Curr Hypertens Rep 16(3):420
39. Parajuli N, Ramprasath T, Patel VB, Wang W, Putko B, Mori J et al (2014) Targeting angiotensin-converting enzyme 2 as a new therapeutic target for cardiovascular diseases. Can J Physiol Pharmacol 92(7):558-565
40. Haschke M, Schuster M, Poglitsch M, Loibner H, Salzberg M, Bruggisser M et al (2013) Pharmacokinetics and pharmacodynamics of recombinant human angiotensinconverting enzyme 2 in healthy human subjects. Clin Pharmacokinet 52:783-792
41. Poglitsch M, DomenigO Schwager C, Stranner S, Peball B, Janzek E et al (2012) Recombinant expression and characterization of human and murine ACE2: species-specific activation of the alternative renin-angiotensin-system. Int J Hypertens 2012:428950